View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


The Medicaid Rebate Summit Keynotes

  • January 13, 2014

  • 2014 Drug Channels Keynote

    MRS Home Page Slider Adam Fein
    Adam J. Fein, PhD

    Pembroke Consulting



    Dr Fein will be opening the MRS 2014 event on February 26th with a keynote address on how Medicaid will Shape Pharma’s Future. More specifically, Dr Fein will address:

    • Key drug channel trends
    • New organizational and
 compliance challenges from
 market developments
    • How Pharmacies, Specialty
 Pharmacies, and PBM’s will be 
affected after full
 implementation of the 
Affordable Care Act
    • Will CMS use AMP-based FUL’s and how that might
 affect pharmacy

    Dr Fein is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry and the author of the popular Drug Channels blog. Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system.

    2013 Keynote is Back By Popular Demand for 2014

    Alice Valder Curran - Medicaid Rebate Summit

    Alice Valder Curran
    Hogan Lovells




    Our 2013 Keynote is back to uncover the most complicated interpretations from the AMP Final Rule

    Topics include:

    • Determining the effect of Bundled Sale Definition on reimbursement rates
    • Uncovering the financial impact of exclusive approval for pediatric indications
    • Deciphering the process for Medicaid coverage of investigational drugs and patient program exclusion criteria
    • Identifying the top ten most complicated aspects of the AMP Final Rule
    • What you should do when you receive covered entity refunds

    Alice Valder Curran’s practice focuses on drug price reporting and healthcare fraud and abuse issues. She has represented numerous pharmaceutical manufacturers in relation to their drug price reporting obligations under the Medicaid, Medicare, and Public Health Service programs.